RevealDx, a Seattle-based startup that develops software aimed at improving the way healthcare professionals diagnose lung cancer, raised $4.25 million in a new investment round.
The company’s product uses machine learning techniques to assess the probability that a lung nodules found on chest CT scans are cancerous.
“We both accelerate diagnosis and reduce false positives,” said RevealDx CEO Chris Wood.
RevealDx was previously known as Mindshare Medical, which was acquired by Precision Medical Ventures in 2021.
Mindshare founder Michael Calhoun is CTO at RevealDx.
Wood told GeekWire that RevealDx has four customers in Europe and is working through FDA approval in the U.S. He declined to provide details on investors or other internal metrics. The company lists four studies under its “clinical validation” section on its website.
Wood is the former CEO of Clario Medical Imaging. He previously founded Seattle health tech company Clario Medical Imaging and led the company from 2005 to 2018. He was also CTO at Intelerad Medical Systems.
https://ift.tt/1vT5EPz July 23, 2024 at 02:30PM GeekWire
Post a Comment
0Comments